Peri-operative blood-loss after total hip arthroplasty can be significantly reduced with topical application of epsilon-aminocaproic acid

Int Orthop. 2016 Oct;40(10):2019-2023. doi: 10.1007/s00264-015-3103-1. Epub 2016 Jan 8.

Abstract

Purpose: To evaluate the peri-operative blood loss with the use of epsilon-aminocaproic acid (ε-ACA) in total hip arthroplasty (THA).

Methods: One hundred sixty patients treated with THA were followed; 5 g ε-ACA diluted in 100 ml normal saline was applied intra-operatively. Eighty patients not receiving ε-ACA (non ε-ACA group) and eighty patients receiving ε-ACA (ε-ACA group) were compared regarding blood loss, need of transfusion, and thrombo-embolic complications.

Results: Blood loss (mean ± SD) for the non ε-ACA group was 1678 ± 515 ml and for the ε-ACA group 1403 ± 417 ml (p < 0.05). In the non ε-ACA group 23 patients needed blood transfusions compared to ten patients in the ε-ACA group (p < 0.05). Cost savings were $284.39 per patient. No patient in either group developed a thrombo-embolic complication.

Conclusions: This study demonstrates a significant reduction in peri-operative blood loss after THA with topically applied ε-ACA. The application of ε-ACA reduced costs by lowering transfusion rates and did not increase thrombo-embolic events. ε-ACA is safe and effective in reducing blood loss and cost-efficient in THA.

Keywords: Blood loss; Epsilon-aminocaproic acid; Total hip arthroplasty.

MeSH terms

  • Administration, Topical
  • Aged
  • Aminocaproic Acid / therapeutic use*
  • Antifibrinolytic Agents / therapeutic use*
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Arthroplasty, Replacement, Hip / methods
  • Blood Loss, Surgical / prevention & control*
  • Blood Transfusion
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Thromboembolism / etiology

Substances

  • Antifibrinolytic Agents
  • Aminocaproic Acid